<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25575" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nasopharyngeal Carcinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Abdul Basit</given-names>
          </name>
          <aff>University of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdul Basit Shah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25575.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Nasopharyngeal carcinoma (NPC), previously known as lymphoepithelioma, is a malignancy arising from the epithelium of the nasopharynx. Endemic to China, the malignancy shows a variable rate of occurrence ranging from high incidence in the Southern part of China to a low rate in the white population and Northern China, with an incidence ranging from 15 to 50 per 100000. The disease is responsible for a complex interplay of genetic susceptibility and Epstein-Barr virus (EBV) infection. This activity describes the incidence, epidemiology, clinical manifestations, evaluation, and treatment of nasopharyngeal carcinoma in detail. It highlights the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology and epidemiology of nasopharyngeal carcinoma.</p></list-item><list-item><p>Assess&#x000a0;the appropriate history and physical and staging evaluation of nasopharyngeal carcinoma.</p></list-item><list-item><p>Differentiate&#x000a0;the treatment and management options available for nasopharyngeal carcinoma.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination and communication to advance care and allow early detection of nasopharyngeal carcinoma and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25575&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25575">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25575.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Nasopharyngeal carcinoma (NPC), previously known as lymphoepithelioma, is an undifferentiated form of squamous cell carcinoma arising from the epithelium of the nasopharynx (see&#x000a0;<bold>Image.</bold>&#x000a0;Nasopharyngeal Mass). It is the most common malignancy of the nasopharynx. Endemic to parts of Asia and Africa but found worldwide, the malignancy shows a variable rate of occurrence ranging from high incidence in the southern part of China (25&#x000a0;to 50 cases per 100,000) to a low rate in European populations (1 case per 100,000).<xref ref-type="bibr" rid="article-25575.r1">[1]</xref>&#x000a0;A complex interplay of genetic susceptibility and Epstein-Barr virus (EBV) infection is responsible for these epidemiological patterns. There is a male predominance.<xref ref-type="bibr" rid="article-25575.r2">[2]</xref></p>
      </sec>
      <sec id="article-25575.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>An interplay of environmental factors, genetic structure, and EBV infection is involved in the etiology of the disease. Environmental factors, including smoking (2&#x000a0;to 6-fold increased risk), heavy alcohol consumption, and nitrosamine-containing food agents, have been considered to have an involvement.<xref ref-type="bibr" rid="article-25575.r3">[3]</xref> Secondly, the genetic structure of the demographics involved also plays a vital role, as explained by the overwhelming incidence in the Chinese population (representing up to 18% of all cancers in parts of southern China and Taiwan).<xref ref-type="bibr" rid="article-25575.r1">[1]</xref>&#x000a0;Lastly, EBV infection, coupled with genetic susceptibility, has shown a substantial relevance to the disease.<xref ref-type="bibr" rid="article-25575.r4">[4]</xref><xref ref-type="bibr" rid="article-25575.r5">[5]</xref></p>
      </sec>
      <sec id="article-25575.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>NPC is endemic to southern China, Southeast Asia, and Africa. The rate varies from a minuscule value of less than 1 per 100,000 individuals in non-endemic areas to a high of 25&#x000a0;to 50 cases per 100,000 males and 15&#x000a0;to 20 cases per 100,000 individuals in females in endemic regions.<xref ref-type="bibr" rid="article-25575.r6">[6]</xref></p>
      </sec>
      <sec id="article-25575.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathological evaluation can elucidate which category the tumor falls in.<xref ref-type="bibr" rid="article-25575.r7">[7]</xref> On histopathological grounds, NPC can fall into&#x000a0;3 main sub-groups as per WHO classification:</p>
        <list list-type="order">
          <list-item>
            <p>Keratinizing type (20% to 25%)</p>
          </list-item>
          <list-item>
            <p>Non-keratinizing differentiated type (10% to 15%)</p>
          </list-item>
          <list-item>
            <p>Non-keratinizing undifferentiated (60% to 65%)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25575.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients can have variable presentations depending on the area of disease involvement. The most common site of origin is the lateral aspect of the nasopharynx and the fossa of Rosenmuller.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Nasal symptoms:</bold>&#x000a0;A subset of&#x000a0;patients&#x000a0;present with nasal symptoms, including nasal obstruction, epistaxis, post-nasal drip, hyponasal speech, or cacosmia. Symptomatology is proportionate to the size of growth and the extent of local involvement&#x02014;around 80% of the individuals suffering from the disease present with nasal symptoms.</p>
          </list-item>
          <list-item>
            <p><bold>Otological symptoms: </bold>Patients may present with symptoms secondary to the tumor obstructing the Eustachian tube, such as conductive hearing loss, middle ear effusion, or aural fullness. An adult with unilateral middle ear effusion requires visualization of the nasopharynx to exclude neoplasm. Half of the patients with NPC have some form of otological complaint during the disease caused by the growing mass obstructing the outflow of the Eustachian tube.</p>
          </list-item>
          <list-item>
            <p><bold>Neurological symptoms:</bold> Intracranial extension is prevalent among 8% to 12% of patients &#x02014; various forms of cranial nerve involvement present with the associated symptom. Cranial nerve palsy is found in 20% of&#x000a0;NPC patients and may be the presenting symptom<xref ref-type="bibr" rid="article-25575.r8">[8]</xref>. The most commonly involved nerve is the abducens nerve.<xref ref-type="bibr" rid="article-25575.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Nodal involvement:</bold>&#x000a0;An enlarged cervical lymph node is&#x000a0;1 of the most common presenting features. Lymph nodes of the apex of the posterior triangle and the upper jugular are initially most commonly involved, together with retropharyngeal nodes. Supraclavicular nodes are the last to be involved and are a sign of advanced disease.<xref ref-type="bibr" rid="article-25575.r10">[10]</xref></p>
          </list-item>
        </list>
        <p><bold>Distant metastasis and paraneoplastic syndrome:</bold> Symptoms associated with distant spread rarely present to the primary caregiver. The most significant spread includes the liver and lungs. It is sometimes difficult to assess the primary site of malignancy when metastatic pulmonary lesions occur. PET scan aids in the differentiation of the&#x000a0;2 (see<bold>&#x000a0;Image.&#x000a0;</bold>PET Scan). Secondly, a handful of cases present with symptoms of dermatomyositis. The progression of the disease might initiate with the malignant lesion or can present after the initial diagnosis of NPC.<xref ref-type="bibr" rid="article-25575.r11">[11]</xref></p>
      </sec>
      <sec id="article-25575.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Lab Investigations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Baseline investigations may include complete blood count, and renal and liver function tests can be obtained if there is a concern for metastasis or paraneoplastic syndrome.</p>
          </list-item>
          <list-item>
            <p>EBV serum IgA levels may carry diagnostic and prognostic significance, particularly in endemic populations.<xref ref-type="bibr" rid="article-25575.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Imaging Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Computed tomography: CT scan with IV contrast is the modality of choice for assessing bone invasion and the extent of some soft tissues, as well as cervical nodal basins (see&#x000a0;<bold>Video.</bold>&#x000a0;Radiologic Imaging Study, Nasopharyngeal Carcinoma).</p>
          </list-item>
          <list-item>
            <p>Magnetic resonance imaging: MRI is the superior modality for assessing intracranial extension, cranial nerve involvement, and defining paranasal sinus involvement. MRI also provides excellent soft-tissue detail when assessing muscle involvement. There is also no radiation exposure with MRI as compared to CT.</p>
          </list-item>
          <list-item>
            <p>PET scan is the modality of choice for assessing remission and investigating recurrence. It is also routinely employed at initial staging to identify distant metastases.</p>
          </list-item>
        </list>
        <p>
<bold>Endoscopic Evaluation and Histopathological Analysis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The nasopharynx is readily accessible for biopsy via endoscopic, trans-nasal routes. If cervical metastases are easily palpable or visualized under ultrasound or CT guidance, they can also be biopsied via fine-needle aspiration.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25575.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The mainstay of treatment for NPC is radiotherapy, with the addition of chemotherapy for advanced-stage disease. Surgical intervention is limited to extremely small primary lesions or small recurrences, as the morbidity of large-scale surgical resection is often significantly more than the morbidity associated with radiotherapy to the region.</p>
        <p>
<bold>Radiotherapy</bold>
</p>
        <p>Radiation therapy is the management of choice for primary lesions and cervical metastases. NPC often metastasizes early to the cervical lymph nodes, and this is frequently a presenting complaint. The tumor also grows locally, involving the paranasopharyngeal spaces and musculature, and may do so with little to no symptoms present. Consequently, a dose of approximately 65 Gy for primary tumors with 50 to 55 Gy is also necessary for node-negative necks. A recent innovation in the delivery system employed for radiation is intensity modulation or intensity-modulated radiotherapy. The system comes equipped with a CT, taking slices of the area involved. The physician specifies the beam's targeted area and modulates the beam's intensity.<xref ref-type="bibr" rid="article-25575.r12">[12]</xref></p>
        <p>Brachytherapy is another innovative technique for targeted radiotherapy. It involves implanting gold grains or iridium implants jacketed for localized radiotherapy via a split incision of the soft palate. This technique is infrequently used in the modern era of intensity-modulated radiotherapy. Radiotherapy is also employed for recurrent NPC. However, repeat radiation to the same area with curative intent depends on the time elapsed since initial treatment and may fall into clinical trials. Radiation therapy can be used for palliative intent as well.<xref ref-type="bibr" rid="article-25575.r5">[5]</xref><xref ref-type="bibr" rid="article-25575.r13">[13]</xref>&#x000a0;</p>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>In&#x000a0;locally advanced&#x000a0;regional diseases, concomitant chemoradiotherapy is the mainstay of management, either via induction or concurrent therapy protocols. The most frequently used initial agent is cisplatin, and the standard of care is a dose of 100 mg every third week. Chemotherapy is also the option of choice when distant metastasis is involved. NPC with distant poly-metastasis is offered palliative chemotherapy. The agents of choice are cisplatin and 5-fluorouracil. With recent advances, several chemotherapeutic agents are available to continue therapy. However, the median survival rate is not more than a year.<xref ref-type="bibr" rid="article-25575.r5">[5]</xref><xref ref-type="bibr" rid="article-25575.r13">[13]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Surgical Intervention</bold>
</p>
        <p>Surgical intervention is employed primarily as a salvage option. The nasopharynx is a small and deep area that is hard to access, thus making the surgical approach sometimes difficult and inappropriate. However, when encountering locally recurring diseases, patients should be given the option of surgical intervention.<xref ref-type="bibr" rid="article-25575.r14">[14]</xref><xref ref-type="bibr" rid="article-25575.r15">[15]</xref>&#x000a0;Nasopharyngectomies can be carried out using several approaches, and the approach chosen should be tailored to the surgeon's expertise and the patient's general condition. The following are some of the popular approaches to the cavity.</p>
        <list list-type="bullet">
          <list-item>
            <p>Inferior approach- via transpalatal incision</p>
          </list-item>
          <list-item>
            <p>Lateral approach- via the lateral skull base</p>
          </list-item>
          <list-item>
            <p>Inferolateral approach</p>
          </list-item>
          <list-item>
            <p>Midfacial degloving</p>
          </list-item>
          <list-item>
            <p>Endoscopic approach</p>
          </list-item>
        </list>
        <p>Neck dissections often accompany the abovementioned procedures, where extensive neck involvement is present. Neck dissection is frequently a component of surgical salvage, particularly in the case of regional recurrence.</p>
      </sec>
      <sec id="article-25575.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for nasopharyngeal carcinoma includes the following:</p>
        <p>Benign Conditions</p>
        <list list-type="bullet">
          <list-item>
            <p>Nasopharyngeal polyposis</p>
          </list-item>
          <list-item>
            <p>Angiofibromas</p>
          </list-item>
          <list-item>
            <p>Antro-choanal polyp</p>
          </list-item>
          <list-item>
            <p>Inverting papilloma</p>
          </list-item>
          <list-item>
            <p>Adenoid hypertrophy</p>
          </list-item>
          <list-item>
            <p>Thornwaldt cyst</p>
          </list-item>
          <list-item>
            <p>Encephalocele</p>
          </list-item>
        </list>
        <p>Malignant Lesions</p>
        <list list-type="bullet">
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Sarcoma</p>
          </list-item>
          <list-item>
            <p>Mucosal melanomas</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25575.s10" sec-type="Staging">
        <title>Staging</title>
        <p>The nuances in imaging techniques and the improved outcomes associated with optimum therapy have caused the American Joint Committee on Cancer (AJCC) to reevaluate the staging process in 2018 (see&#x000a0;<bold>Image.</bold>&#x000a0;Staging Table).<xref ref-type="bibr" rid="article-25575.r16">[16]</xref> As per the recent guidelines, the TNM staging has been defined as:</p>
        <p>
<bold>Primary Tumor (T)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>T0:</bold> No primary tumor identified (but with EBV-positive cervical node)</p>
          </list-item>
          <list-item>
            <p><bold>Tis: </bold>Carcinoma <italic toggle="yes">in situ</italic>, no invasive tumor present</p>
          </list-item>
          <list-item>
            <p><bold>T1:</bold> Tumor involves nasopharynx, oropharynx, and/or nasal cavity without parapharyngeal involvement</p>
          </list-item>
          <list-item>
            <p><bold>T2:</bold> Tumor extension into the parapharyngeal spaces or adjacent soft tissue (pterygoids, prevertebral muscles)</p>
          </list-item>
          <list-item>
            <p><bold>T3:</bold> Tumor involves bony skull base, pterygoid bones, paranasal sinuses, cervical vertebrae</p>
          </list-item>
          <list-item>
            <p><bold>T4:</bold>Tumor involves intracranial extension, deficits of cranial nerves, hypopharynx, orbit, parotid gland, and/or soft tissue infiltration beyond the lateral surface of the lateral pterygoid</p>
          </list-item>
        </list>
        <p>
<bold>Nodal metastasis (N)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>N0:</bold> No involvement</p>
          </list-item>
          <list-item>
            <p><bold>N1:</bold> Unilateral cervical or unilateral or bilateral retropharyngeal node(s), &#x02264; 6 cm in greatest dimension, all located above the caudal border of the cricoid cartilage</p>
          </list-item>
          <list-item>
            <p><bold>N2:</bold> Bilateral cervical node(s), &#x02264; 6 cm in greatest dimension, all located above the caudal border of the cricoid cartilage</p>
          </list-item>
          <list-item>
            <p><bold>N3:&#x000a0;</bold>Unilateral or bilateral cervical node(s) &#x0003e; 6 cm in greatest dimension or located below the caudal border of the cricoid cartilage</p>
          </list-item>
        </list>
        <p>
<bold>Distant Metastasis (M)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>M0:</bold> No distant metastases</p>
          </list-item>
          <list-item>
            <p><bold>M1:</bold> Distant metastases present</p>
          </list-item>
        </list>
        <p>
<bold>Stage Grouping</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage 0:&#x000a0;</bold>T1s-N0-M0</p>
          </list-item>
          <list-item>
            <p><bold>Stage I:&#x000a0;</bold>T1-N0-M0</p>
          </list-item>
          <list-item>
            <p><bold>Stage II:&#x000a0;</bold>T1-N1-M0 and&#x000a0;T2-N0, N1-M0&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Stage III:&#x000a0;</bold>T1, T2, T3-N2-M0 and&#x000a0;T3-N0, N1, N2-M0</p>
          </list-item>
          <list-item>
            <p><bold>Stage IVA:&#x000a0;</bold>T4-any N-M0 and Any T, N3-M0</p>
          </list-item>
          <list-item>
            <p><bold>Stage IVB:&#x000a0;</bold>Any T-any N, M1&#x000a0;(see&#x000a0;<bold>Image.</bold>&#x000a0;Stage Grouping Table)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25575.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The overall prognosis and the 5-year survival rate have improved with improved radiotherapy techniques. This has resulted in reported 5-year&#x000a0;survival rates increasing from 25% to 40% historically to approximately 70% in the modern treatment era.<xref ref-type="bibr" rid="article-25575.r17">[17]</xref></p>
      </sec>
      <sec id="article-25575.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Obstruction of Eustachian tubes causing otitis media with effusion is the most common complication, but persistent nasal obstruction and obstruction of the oropharyngeal airway are also possible. Intracranial extension and involvement of cranial nerves are debilitating. They can have a lifelong disability even after management, as the return of cranial nerve function is not always possible even after the malignancy has been treated. More than&#x000a0;1 cranial nerve deficit is a poor prognostic sign.<xref ref-type="bibr" rid="article-25575.r18">[18]</xref></p>
      </sec>
      <sec id="article-25575.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations that are typically requested for patients with this condition include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Otolaryngology - nasopharyngeal biopsy and placement of tympanostomy tube</p>
          </list-item>
          <list-item>
            <p>Pathology or radiology - FNA of cervical lymph node</p>
          </list-item>
          <list-item>
            <p>Radiation oncology - definitive treatment</p>
          </list-item>
          <list-item>
            <p>Hematology/Oncology - concurrent chemotherapy</p>
          </list-item>
          <list-item>
            <p>Psychiatry - mental health in the setting of a new cancer diagnosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25575.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients endemic to prevalent areas should be more vigilant regarding the symptoms of the disease. Moreover, the demographics of the Western population with environmental factors (smoking, etc) associated with NPC should also receive education regarding their hazardous effects. Also, the subset of people having genetic susceptibility along with recurrent EBV infection should have a higher index of suspicion for the disease.</p>
      </sec>
      <sec id="article-25575.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about nasopharyngeal carcinoma are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>NPC is a malignancy having a variable incidence depending on the region.</p>
          </list-item>
          <list-item>
            <p>Endoscopic biopsy should be the first and foremost step in evaluating the lesion.</p>
          </list-item>
          <list-item>
            <p>NPC has a high index of susceptibility to radiotherapy, and this forms the mainstay of treatment at nearly every stage</p>
          </list-item>
          <list-item>
            <p>In advanced cases, chemotherapy is given concomitantly to produce optimum results. The drug of choice is cisplatin.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25575.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>After diagnosis, a radiotherapist and oncologist should educate the patient regarding the favorable outcome of strict adherence to the program. Otolaryngology and otolaryngology nurses provide care and education to these patients after nasopharyngeal biopsy and regarding hearing optimization, if Eustachian tube dysfunction is present. Board-certified oncologic pharmacists review prescriptions and check for drug-drug interactions. Oncology specialty nursing staff can administer chemotherapy, assist in post-procedural care and monitoring, and report any concerns to the treating clinicians.</p>
        <p>All these interprofessional team members are tasked with keeping meticulous patient records so that everyone involved in the patient's care has the most accurate and updated information, and everyone must maintain open communication lines so interventions can be promptly initiated when needed. Also, patients having the psychological burden of a malignant diagnosis benefit from structured support groups and psychologist sessions, so mental health practitioners should also be part of the interprofessional team.</p>
      </sec>
      <sec id="article-25575.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25575&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25575">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/nasopharyngeal-carcinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25575">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25575/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25575">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25575.s18">
        <fig id="article-25575.image.f1" position="float" orientation="portrait">
          <caption>
            <p>PET Scan.&#x000a0;A patient's scan shows a hypermetabolic soft tissue lesion measuring 13 x 10 mm in the right nasopharynx. Contributed by A Basit</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="STAT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25575.s19">
        <fig id="article-25575.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Nasopharyngeal Mass. CT image of a patient with a left-sided nasopharyngeal mass involving the posterior pharyngeal wall and showing minor opacification of the maxillary antrum bilateral. Contributed by A Basit</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="20191228_173639" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25575.s20">
        <fig id="article-25575.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Staging Table Contributed by AB Shah, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Staging__Table__01" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25575.s21">
        <fig id="article-25575.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Stage Grouping Table&#x000a0; Contributed by AB Shah, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Staging__Table__02" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25575.s22">
        <fig id="article-25575.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Radiologic Imaging Study, Nasopharyngeal Carcinoma. Radiologic imaging study of a 53-year-old male patient who had been operated&#x000a0;on for a nasopharyngeal carcinoma 5 years ago. Contributed by M &#x000d6;zdemir, MD</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="5.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25575.s23">
        <title>References</title>
        <ref id="article-25575.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Adami</surname>
                <given-names>HO</given-names>
              </name>
            </person-group>
            <article-title>The enigmatic epidemiology of nasopharyngeal carcinoma.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1765</fpage>
            <page-range>1765-77</page-range>
            <pub-id pub-id-type="pmid">17035381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Du</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>e0219611</fpage>
            <pub-id pub-id-type="pmid">31291379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jicman Stan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Niculet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lungu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onisor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rebegea</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vesa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bezman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bujoreanu</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Sarbu</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Mihailov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fotea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tatu</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Nasopharyngeal carcinoma: A new synthesis of literature data (Review).</article-title>
            <source>Exp Ther Med</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <pub-id pub-id-type="pmid">35069817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Association of Plasma Epstein-Barr Virus LMP1 and EBER1 with Circulating Tumor Cells and the Metastasis of Nasopharyngeal Carcinoma.</article-title>
            <source>Pathol Oncol Res</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>1893</fpage>
            <page-range>1893-1901</page-range>
            <pub-id pub-id-type="pmid">31832991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adoga</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kokong</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Ma'an</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Silas</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Dauda</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Yaro</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mugu</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Mgbachi</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yabak</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology, treatment, and determinants of outcome of primary head and neck cancers at the Jos University Teaching Hospital.</article-title>
            <source>South Asian J Cancer</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-187</page-range>
            <pub-id pub-id-type="pmid">30112335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Simons</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>The prevalence and prevention of nasopharyngeal carcinoma in China.</article-title>
            <source>Chin J Cancer</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-9</page-range>
            <pub-id pub-id-type="pmid">21272443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.</article-title>
            <source>Radiother Oncol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>104</volume>
            <issue>3</issue>
            <fpage>286</fpage>
            <page-range>286-93</page-range>
            <pub-id pub-id-type="pmid">22995588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denton</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Khunger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reyes-Corcho</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Case of Nasopharyngeal Carcinoma Presenting With Rare Combination of Multiple Cranial Nerve Palsies.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>e20357</fpage>
            <pub-id pub-id-type="pmid">35028234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mo</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>HQ</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of pretreatment and recovery duration of cranial nerve palsy in nasopharyngeal carcinoma.</article-title>
            <source>Radiat Oncol</source>
            <year>2012</year>
            <month>Sep</month>
            <day>07</day>
            <volume>7</volume>
            <fpage>149</fpage>
            <pub-id pub-id-type="pmid">22958729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batsakis</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>The pathology of head and neck tumors: carcinoma of the nasopharynx, Part 11.</article-title>
            <source>Head Neck Surg</source>
            <year>1981</year>
            <season>Jul-Aug</season>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-24</page-range>
            <pub-id pub-id-type="pmid">7251374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teoh</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Yunus</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ghazali</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abidin</surname>
                <given-names>ZA</given-names>
              </name>
            </person-group>
            <article-title>Nasopharyngeal carcinoma in dermatomyositis patients: A 10-year retrospective review in Hospital Selayang, Malaysia.</article-title>
            <source>Rep Pract Oncol Radiother</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>332</fpage>
            <page-range>332-6</page-range>
            <pub-id pub-id-type="pmid">25184058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garden</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Straube</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Glisson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Quivey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thorstad</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ang</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Aug</month>
            <day>01</day>
            <volume>27</volume>
            <issue>22</issue>
            <fpage>3684</fpage>
            <page-range>3684-90</page-range>
            <pub-id pub-id-type="pmid">19564532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanchard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moya-Plana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pignon</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Even</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bidault</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Temam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruffier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[New developments in the management of nasopharyngeal carcinoma].</article-title>
            <source>Cancer Radiother</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>6-7</issue>
            <fpage>492</fpage>
            <page-range>492-495</page-range>
            <pub-id pub-id-type="pmid">30087054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Salvage endoscopic nasopharyngectomy for local recurrent or residual nasopharyngeal carcinoma: a 10-year experience.</article-title>
            <source>Int J Clin Oncol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>834</fpage>
            <page-range>834-842</page-range>
            <pub-id pub-id-type="pmid">28601934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tharavai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oakley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cascarini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guerro-Urbano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jeannon</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of salvage surgery for the oropharynx and larynx: a contemporary experience in a UK Cancer Centre.</article-title>
            <source>Eur Arch Otorhinolaryngol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>276</volume>
            <issue>4</issue>
            <fpage>1153</fpage>
            <page-range>1153-1159</page-range>
            <pub-id pub-id-type="pmid">30666441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Edge</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Brookland</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Winchester</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-99</page-range>
            <pub-id pub-id-type="pmid">28094848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.</article-title>
            <source>Int J Biol Sci</source>
            <year>2018</year>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>549</fpage>
            <page-range>549-556</page-range>
            <pub-id pub-id-type="pmid">29805306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25575.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>WI</given-names>
              </name>
            </person-group>
            <article-title>The role of myringotomy and ventilation tube insertion in maxillary swing approach nasopharyngectomy: review of our 10-year experience.</article-title>
            <source>Laryngoscope</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>123</volume>
            <issue>2</issue>
            <fpage>376</fpage>
            <page-range>376-80</page-range>
            <pub-id pub-id-type="pmid">22951935</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
